Clarify the Role of Inbrija for Parkinson's Disease

May 2019

Inbrija (in-BREE-jah) will be the first INHALED levodopa for adults with Parkinson's disease.

Think of Inbrija as a fast-acting levodopa...it starts to work in about 10 minutes and lasts about an hour. It joins the only other "on demand" option...Apokyn (apomorphine), a subcutaneous injection.

Inbrija is used as needed to treat "off" episodes...when scheduled carbidopa/levodopa wears off between doses and symptoms (rigidity, tremor, etc) return, especially as Parkinson's progresses.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote